I-install ang ginto presyo kasangkapan!
Historical Gold Silver Presyo
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1989
1988
1987
1986
1985
1984
1983
1982
1981
1980
1979
1978
1977
1976
1975
1974
1973
1972
1971
1970
1969
1968
|
2018/08/11
| USD / onsa | |
| Gold | | |
| Silver | |
Gold Historical Gold Presyo Tsart at Graph
360 araw graph ,
1 Ounce Gold=? USD
Silver Historical Silver Presyo ng Tsart at Graph
360 araw graph ,
1 Ounce Silver=? USD
ginto balita:
- FDA expands approval of Modernas RSV vaccine to some adults under age . . .
The U S Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease
- Moderna Receives U. S. FDA Approval for RSV Vaccine, mRESVIA, in Adults . . .
Expanded indication builds on existing U S FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA ACCESS Newswire June 12, 2025 Moderna, Inc (NASDAQ:MRNA) today announced that the U S Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD
- FDA expands approval for Modernas RSV vaccine - The Hill
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from
- US FDA Approves Expanded Use of Modernas RSV Vaccine for At-Risk Adults
The FDA approved mRESVIA in adults aged 60 or older last year, but with a lower efficacy label indicating the shot was 79% effective at preventing at least two symptoms of RSV, such as cough and
- FDA approves Moderna RSV vaccine use for people aged 18 to 59 - STAT
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they
- Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger . . .
The expanded approval now includes individuals aged 18 to 59 who are at risk of RSV This approval was supported by results from Moderna’s Phase III study (NCT06067230), which demonstrated the vaccine’s immune response worked just as well in this age group compared to the existing approved age group of 60 years and older
- Moderna wins FDA OK to widen use of RSV vaccine
The FDA cleared Moderna's RSV shot for use in certain adults between the ages of 18 and 59 on June 12, 2025 The Food and Drug Administration has approved wider use of Moderna’s respiratory syncytial virus vaccine in a boost for a company that’s been negatively impacted by the recent leadership changes atop U S public health agencies
- MRESVIA | FDA - U. S. Food and Drug Administration
Rolling BLA (Part 1 of 2) - Active immunization for the prevention of lower respiratory tract disease (LRTD) and acute respiratory disease (ARD) caused by respiratory syncytial virus (RSV) in
- FDA Approves Moderna’s mResvia for Prevention of Severe . . . - MedCentral
On May 31, the US Food and Drug Administration (FDA) approved Moderna’s mRESVIA (mRNA-1345), an mRNA-based vaccine for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease (RSV-LRTD) in adults aged 60 years and older
- FDA nod for Moderna’s RSV Vaccine, mRESVIA for younger adults
US mRNA specialist Moderna today announced that the US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), the company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease
|
|
ginto presyo, bumili ng ginto, nagbebenta ng ginto ©2005-2009
|Currency Exchange Rate
|disclaimer
|